ENGNenGene Therapeutics Inc.vs its industry peers
A metric-by-metric comparison of enGene Therapeutics Inc. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ENGNEsta | $127M#9 | 0.8x#1 | 0.6x#1 | — | — | -112.7%#11 | — | -50.9%#6 | — | — | -69.6%#4 | — |
| HUMA | $159M#3 | — | 5.1x#10 | 78.0x#7 | — | 72.5%#4 | -5306.0%#7 | -130.6%#9 | — | — | — | — |
| ARMP | $155M#4 | — | — | — | — | -818.8%#13 | — | — | — | — | — | 0.1%#1 |
| TNYA | $149M#5 | — | 2.2x#6 | — | — | 18.5%#6 | — | -130.5%#8 | — | — | — | — |
| NMRA | $147M#6 | — | 3.3x#8 | — | — | -2.8%#9 | — | 532.2%#2 | -594.0%#2 | — | — | — |
| CRBU | $140M#7 | — | 1.4x#5 | 12.5x#6 | 11.7%#2 | 0.7%#7 | -1329.4%#6 | -151.0%#10 | — | — | — | — |
| LENZ | $130M#8 | — | 0.6x#2 | 6.8x#5 | — | -65.0%#10 | -477.5%#5 | -37.5%#5 | — | — | — | — |
| BDTX | $113M#10 | — | 1.2x#4 | 1.6x#3 | — | 132.1%#2 | 17.9%#2 | 23276.9%#1 | — | — | — | — |
| ATTO | $1.1B#1 | — | — | — | — | — | — | — | — | — | — | — |
| CRDF | $102M#11 | — | 3.8x#9 | 171.2x#8 | -13.2%#4 | -0.9%#8 | -8256.3%#8 | -0.2%#4 | — | — | -35.1%#3 | — |
| CGTX | $101M#12 | — | 3.1x#7 | — | — | 30.9%#5 | — | -71.1%#7 | — | — | — | — |
| ATRA | $100M#13 | — | — | 0.8x#2 | -6.3%#3 | 138.3%#1 | 29.7%#1 | — | — | — | -16.2%#1 | — |
| PTHS | $84M#14 | — | — | 5.0x#4 | — | -444.6%#12 | -193.1%#4 | — | — | — | — | — |
| SCTX | $615M#2 | — | — | — | — | — | — | — | — | — | — | — |
| VXRT | $80M#15 | 2.0x#2 | 1.0x#3 | 0.3x#1 | 726.7%#1 | 124.4%#3 | 7.6%#3 | 0.0%#3 | 22.5%#1 | — | -24.0%#2 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-09-17.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice